Intercept prices IPO; Long-term safety study backs Pfizer pain drug; First tenant for Elk Run?;

Conversations on Twitter :

 @FierceBiotech: New special report: Top diabetes drug pipelines of 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Kythera IPO prices at high end of range (I don't write that very often). More | Follow @JohnCFierce

 @RyanMFierce: GSK will decide whether to grant access to the ID-less patient data based on scientific merit. Sounds subjective, but progress nonetheless. | Follow @RyanMFierce

> Intercept Pharmaceuticals says it has priced its 5 million IPO shares at $15, ahead of underwriting discounts. Release

> Pfizer ($PFE) says its pain drug ALO-02 demonstrated a long-term safety profile which was comparable to similar drugs. Story

> Tengion, a struggling regenerative medicine company in North Carolina, has completed a $15 million note offering with investors Celgene, RA Capital Management, Deerfield Management Company, Bay City Capital and HealthCap. Release

Pharma News

@FiercePharma: India's pharma industry is the country's 2nd-best at making billionaires. More | Follow @FiercePharma

> Minister: Jobs at Sanofi's Toulouse site mostly safe. Story

> Another compounding group shuts amid outbreak. Article

> Glaxo pledges to unveil all trial data, good, bad or ugly. Item

Medical Device News

 @FierceMedDev: As BSX has implied, the job cuts are coming. More | Follow @FierceMedDev

 @MarkHFierce: Not only is angel investing recovering, but much of it seems to be hitting medical device startups. More | Follow @MarkHFierce

 @DamianFierce: Four former Synthes execs have been effectively blacklisted from the life sciences industry. More | Follow @DamianFierce

> J&J's Cordis touts stent for femoral artery disease. Story

> Medical devices drive the start of an angel investor rebound. Item

> Quest Diagnostics slashing 400-600 jobs to save $65M. More

Pharma Manufacturing News

> Novasep investing in another API expansion. News

> Auctus Pharma API plant in India catches fire. Report

> Merck opens $21M Jakarta packaging plant. Story

Vaccines News

> GSK, Aeras partner for TB vaccine trial. More

> Merck taps Vaxxas for Nanopatch vaccine delivery. Story

> Pfizer's Prevnar 13 posts positive late-stage data. Report

> Takeda snaps up LigoCyte for $60M. Item

And Finally… Three years after it was first announced with great fanfare, the Elk Run biotech campus in Minnesota may have just snagged its first tenant. Readers are cautioned, though, that earlier hopes have been repeatedly quashed. Story

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.